Article
Infectious Diseases
Leigh M. Howard, Xiang Huang, Wencong Chen, Yuhan Liu, Kathryn M. Edwards, Marie R. Griffin, Yuwei Zhu, Jorge E. Vidal, Keith P. Klugman, Ana I. Gil, Nicole R. Soper, Isaac P. Thomsen, Katherine Gould, Jason Hinds, Claudio F. Lanata, Carlos G. Grijalva
Summary: We investigated the association between nasopharyngeal pneumococcal co-colonization and pneumococcal density in young Peruvian children. Pneumococcal co-colonization was common but not associated with increased pneumococcal density.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Kristina L. Bajema, Ryan Gierke, Monica M. Farley, William Schaffner, Ann Thomas, Arthur L. Reingold, Lee H. Harrison, Ruth Lynfield, Kari E. Burzlaff, Susan Petit, Meghan Barnes, Salina Torres, Paula M. Snippes Vagnone, Bernard Beall, Tamara Pilishvili
Summary: The incidence of antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) has decreased in the United States after the introduction of 7- and 13-valent pneumococcal conjugate vaccines (PCVs). However, there has been an increase in nonvaccine type NS-IPD, particularly among older adults. The use of higher valency PCVs containing the common nonsusceptible serotypes could help further reduce NS-IPD.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Ari Prayitno, Bambang Supriyatno, Zakiudin Munasir, Anis Karuniawati, Sri Rezeki S. Hadinegoro, Joedo Prihartono, Dodi Safari, Julitasari Sundoro, Miftahuddin Majid Khoeri
Summary: The PCV13 immunization demonstration program in Indonesia showed a significant decrease in dominant serotypes, especially 6A/6B, in infants' nasopharynx after vaccination. This suggests that the PCV13 vaccine has a certain efficacy in reducing pathogen colonization in infants' nasopharynx.
Article
Immunology
Leore Kotler, David Greenberg, Noga Givon-Lavi, Bart Adriaan van der Beek, Ron Dagan, Shalom Ben-Shimol
Summary: The study evaluated the impact of PCV on pneumococcal carriage rates in healthy and sick children aged 6-23 months, showing a decrease in carriage rates in respiratory diseases but not in healthy children and those without respiratory infections. This suggests a reduction in respiratory infections caused by VT with a stable rate of non-VT in non-respiratory cases.
Article
Immunology
Adriano P. Araujo, Maria Leonor S. Oliveira, Eliane N. Miyaji
Summary: Streptococcus pneumoniae colonizes the human nasopharynx asymptomatically, but can cause various diseases. This study demonstrates the important role of PspA and PspC in nasopharyngeal colonization, although their significance may vary between different strains.
MICROBIAL PATHOGENESIS
(2023)
Article
Multidisciplinary Sciences
Thiago Rojas Converso, Cibelly Goulart, Dunia Rodriguez, Maria Eduarda Souza Guerra, Michelle Darrieux, Luciana C. C. Leite
Summary: The hybrid protein rPotD-PdT can induce stronger immune responses, but is not sufficient to provide full protection against highly virulent pneumococcal strains. Therefore, combination with other antigens may be necessary for sufficient protection.
Article
Immunology
Karolina Kielbik, Aleksandra Pietras, Joanna Jablonska, Adrian Bakiera, Anna Borek, Grazyna Niedzielska, Michal Grzegorczyk, Ewelina Grywalska, Izabela Korona-Glowniak
Summary: Poland introduced the 10-valent pneumococcal conjugate vaccine (PCV) in 2017 and conducted a study to evaluate its impact on the colonization of Streptococcus pneumoniae in healthy children. The study found that the colonization rate was slightly higher in vaccinated children compared to unvaccinated children. Additionally, the study identified an increase in antibiotic resistance among certain pneumococcal serotypes and a modest increase in colonization by non-vaccine serotypes.
Article
Public, Environmental & Occupational Health
Aditi Apte, Girish Dayma, Hakka Naziat, Linda Williams, Sonali Sanghavi, Jamal Uddin, Anand Kawade, Maksuda Islam, Sanchita Kar, You Li, Moe H. Kyaw, Sanjay Juvekar, Harry Campbell, Harish Nair, Samir K. Saha, Ashish Bavdekar
Summary: This study found that South Asian infants get colonised with pneumococci early in infancy, with the Indian cohort predominantly carrying vaccine serotypes in a PCV naive population, while the Bangladeshi cohort mainly carrying non-vaccine serotypes in a vaccinated population. These local findings are important for informing public health policy and developing higher valent pneumococcal vaccines.
JOURNAL OF GLOBAL HEALTH
(2021)
Article
Immunology
Louise K. Francois Watkins, Jennifer L. Milucky, Lesley McGee, Florence Sine St-Surin, Pengbo Liu, Theresa Tran, Sopio Chochua, Gerard Joseph, Nong Shang, Stanley Juin, Patrick Dely, Roopal Patel, Chris A. Van Beneden
Summary: In Port-au-Prince, Haiti, approximately a quarter of healthy children were colonized with vaccine-type pneumococcal serotypes, indicating potential impact of PCV13 introduction nationwide in reducing pneumococcal carriage.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Joseph A. Lewnard, Noga Givon-Lavi, Ron Dagan
Summary: The study analyzed the effectiveness of PCV in protecting children against pneumonia caused by different vaccine-targeted pneumococcal serotypes in southern Israel. The results showed that PCV could effectively reduce carriage of vaccine-serotype pneumococci and decrease the risk of disease progression.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Kristin Andrejko, Buddhika Ratnasiri, Joseph A. Lewnard
Summary: This study reviewed the antimicrobial susceptibility of pneumococcal serotypes among children globally. The results showed geographical and temporal variation in nonsusceptibility, which was associated with biological characteristics of the serotypes. The implementation of PCVs led to an increase in nonsusceptibility among non-PCV serotypes.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Brandon Essink, Charu Sabharwal, Kevin Cannon, Robert Frenck, Himal Lal, Xia Xu, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Michael W. Pride, Ingrid L. Scully, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Summary: The 20-valent pneumococcal conjugate vaccine (PCV20) has shown to be safe and well tolerated, with immunogenicity comparable to that of the 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide vaccine. PCV20 is expected to provide expanded protection against pneumococcal disease in adults.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Shahira Shahid, Amala Khan, Muhammad Imran Nisar, Farah Khalid, Muhammad Farrukh Qazi, Sheraz Ahmed, Furqan Kabir, Aneeta Hotwani, Sahrish Muneer, Syed Asad Ali, Cynthia G. Whitney, Anita K. M. Zaidi, Fyezah Jehan
Summary: The 10-valent pneumococcal vaccine was introduced in Pakistan's Expanded Program on Immunization (EPI) in 2013. Three annual cross-sectional surveys were conducted from 2014-2016, showing a significant decrease in vaccine-type carriage in infants.
Article
Immunology
Ron Dagan, Qin Jiang, Christine Juergens, James Trammel, William C. Gruber, Daniel A. Scott
Summary: This study found that carrier-induced hyporesponsiveness to PCVs is common among infants, varies by serotype, and is influenced by the timing of carriage acquisition and the number of PCV doses administered. The immune response was consistently lower for certain serotypes carried before or at the time of vaccination, while other serotypes did not generally affect immune responses. Additionally, the study identified a complex interrelationship between carriage and immune response among cross-reacting serotypes.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Lassane Kabore, Tolulope Adebanjo, Berthe Marie Njanpop-Lafourcade, Soumeya Ouangraoua, Felix T. Tarbangdo, Bertrand Meda, Srinivasan Velusamy, Brice Bicaba, Flavien Ake, Lesley McGee, Seydou Yaro, Edouard Betsem, Alain Gervaix, Bradford D. Gessner, Cynthia G. Whitney, Jennifer C. Moisi, Chris A. Van Beneden
Summary: Within 3 years of PCV13 implementation in Burkina Faso, substantial reductions in the percentage of pneumococcal carriers with a vaccine-type were documented among children under 5 years old, but not among individuals aged 5 years and above. More time, a change in the PCV13 schedule, or both, may be needed to better control pneumococcal carriage in this setting.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Ron Dagan, Shalom Ben-Shimol, David Greenberg, Noga Givon-Lavi
Summary: This study examined the impact of pneumococcal conjugate vaccines (PCVs) on bacterial conjunctivitis incidence in children aged 2-23 months in southern Israel. The implementation of PCV13 resulted in a significant decline in disease caused by PCV13 serotypes without significant replacement by non-PCV13 serotypes. The findings suggest a marked reduction in overall conjunctivitis rates in children under 2 years of age.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Anne L. Wyllie, Joshua L. Warren, Gili Regev-Yochay, Noga Givon-Lavi, Ron Dagan, Daniel M. Weinberger
Summary: The frequency of serotypes causing IPD differs between adults and children, as well as between older and younger adults and adults with and without comorbidities. Older children, rather than infants, were found to have a better correlation with the serotype-specific IPD patterns in adults, indicating they may play a more influential role in disease patterns. These findings could help optimize vaccination strategies to reduce disease burden across different age groups.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Joseph A. Lewnard, Noga Givon-Lavi, Ron Dagan
Summary: The study analyzed the effectiveness of PCV in protecting children against pneumonia caused by different vaccine-targeted pneumococcal serotypes in southern Israel. The results showed that PCV could effectively reduce carriage of vaccine-serotype pneumococci and decrease the risk of disease progression.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Ron Dagan, Shalom Ben-Shimol, Rachel Benisty, Gili Regev-Yochay, Stephanie W. Lo, Stephen D. Bentley, Paulina A. Hawkins, Lesley McGee, Merav Ron, Noga Givon-Lavi, Lea Valinsky, Assaf Rokney
Summary: In Israel during the PCV13 era, an outbreak of Sp2 IPD caused by the emerging ST-13578 clone was identified. This clone, mainly found in the Jewish population and specific regions of Israel, showed clonality and likely evolved from ST-1504 through recombination processes.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
Summary: The study demonstrates that the 7-valent and 13-valent pneumococcal vaccines are effective in protecting against otitis media caused by specific serotypes, especially serotypes 19F and 19A.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Maria Deloria Knoll, Julia C. Bennett, Maria Garcia Quesada, Eunice W. Kagucia, Meagan E. Peterson, Daniel R. Feikin, Adam L. Cohen, Marissa K. Hetrich, Yangyupei Yang, Jenna N. Sinkevitch, Krow Ampofo, Laurie Aukes, Sabrina Bacci, Godfrey Bigogo, Maria-Cristina C. Brandileone, Michael G. Bruce, Romina Camilli, Jesus Castilla, Guanhao Chan, Grettel Chanto Chacon, Pilar Ciruela, Heather Cook, Mary Corcoran, Ron Dagan, Kostas Danis, Sara de Miguel, Philippe De Wals, Stefanie Desmet, Yvonne Galloway, Theano Georgakopoulou, Laura L. Hammitt, Markus Hilty, Pak-Leung Ho, Sanjay Jayasinghe, James D. Kellner, Jackie Kleynhans, Mirjam J. Knot, Jana Kozakova, Karl Gustaf Kristinsson, Shamez N. Ladhani, Claudia S. Lara, Maria Eugenia Leon, Tiia Lepp, Grant A. Mackenzie, Lucia Mad'arova, Allison McGeer, Tuya Mungun, Jason M. Mwenda, J. Pekka Nuorti, Nehemie Nzoyikorera, Lucia Helena De Oliveira, Metka Paragi, Tamara Pilishvili, Rodrigo Puentes, Eric Rafai, Samir K. Saha, Larisa Savrasova, Camelia Savulescu, J. Anthony Scott, Kevin J. Scott, Fatima Serhan, Lena Petrova Setchanova, Nadja Sinkovec Zorko, Anna Skoczynska, Todd D. Swarthout, Palle Valentiner-Branth, Mark van Der Linden, Didrik E. Vestrheim, Anne von Gottberg, Inci Yildirim, Kyla Hayford
Summary: This study provides a comprehensive overview of serotype-specific IPD surveillance in countries using PCV10/13, with a focus on the PSERENADE project. The analysis includes data from multiple sites across geographic regions and different vaccination schedules, aiming to estimate the impact of PCV and inform decision-making at national and global levels.
Article
Microbiology
Maria Garcia Quesada, Yangyupei Yang, Julia C. Bennett, Kyla Hayford, Scott L. Zeger, Daniel R. Feikin, Meagan E. Peterson, Adam L. Cohen, Samanta C. G. Almeida, Krow Ampofo, Michelle Ang, Naor Bar-Zeev, Michael G. Bruce, Romina Camilli, Grettel Chanto Chacon, Pilar Ciruela, Cheryl Cohen, Mary Corcoran, Ron Dagan, Philippe De Wals, Stefanie Desmet, Idrissa Diawara, Ryan Gierke, Marcela Guevara, Laura L. Hammitt, Markus Hilty, Pak-Leung Ho, Sanjay Jayasinghe, Jackie Kleynhans, Karl G. Kristinsson, Shamez N. Ladhani, Allison McGeer, Jason M. Mwenda, J. Pekka Nuorti, Kazunori Oishi, Leah J. Ricketson, Juan Carlos Sanz, Larisa Savrasova, Lena Petrova Setchanova, Andrew Smith, Palle Valentiner-Branth, Maria Teresa Valenzuela, Mark van der Linden, Nina M. van Sorge, Emmanuelle Varon, Brita A. Winje, Inci Yildirim, Jonathan Zintgraff, Maria Deloria Knoll
Summary: Introduction of PCV has reduced pneumococcal meningitis incidence, with remaining cases showing different serotype distribution in countries using PCV10/13 for at least 5-7 years. Higher-valency PCVs may target over half of remaining cases, but further data is needed for generalizability in the African meningitis belt.
Article
Immunology
Dana Danino, Bart Adriaan van der Beek, Noga Givon-Lavi, David Greenberg, Shalom Ben-Shimol, Ron Dagan
Summary: Following the implementation of pneumococcal conjugate vaccines, the prescription rate of antibiotics for children under 5 years of age decreased significantly within a short period of time and stabilized within 5 years, mainly driven by drugs like amoxicillin. Children under 2 years of age and Bedouin ethnicity had higher antibiotic prescription rates before PCV implementation, but saw a faster decline post-PCV, nearly eliminating the gaps between different age groups and ethnicities.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Shalom Ben-Shimol, Gili Regev-Yochay, Noga Givon-Lavi, Bart Adriaan van der Beek, Tal Brosh-Nissimov, Avi Peretz, Orli Megged, Ron Dagan
Summary: A ten-year surveillance after the implementation of PCV7/PCV13 showed a significant reduction in invasive pneumococcal disease in children and adults, with stabilization after four years. The main PCV13 serotypes were 3, 19A, and 14, while serotypes 8 and 12F were the predominant nonvaccine serotypes.
CLINICAL INFECTIOUS DISEASES
(2022)
Correction
Immunology
Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Yaniv Faingelernt, Ron Dagan, Noga Givon-Lavi, Bart Adriaan van der Beek, Shalom Ben-Shimol, Eilon Shany, David Greenberg
Summary: The implementation of PCV vaccination in Israel has led to a reduction in CAAP incidence in both preterm-born and term-born infants. The reduction rate was higher in outpatients compared to hospitalized children, and the disparity in CAAP rates between preterm-born and term-born infants was also reduced.
Article
Immunology
R. A. Gladstone, L. Siira, O. B. Brynildsrud, D. F. Vestrheim, P. Turner, S. C. Clarke, S. Srifuengfung, R. Ford, D. Lehmann, E. Egorova, E. Voropaeva, G. Haraldsson, K. G. Kristinsson, L. McGee, R. F. Breiman, S. D. Bentley, C. L. Sheppard, N. K. Fry, J. Corander, M. Toropainen, A. Steens
Summary: This study used genomics to investigate the international links between outbreaks of vaccine preventable serotype 4 sequence type 801 in shipyards in several countries. The findings suggest that the total diversity of ST801 within the outbreaks cannot be solely explained by recent transmission alone, indicating potential international transmission between shipyards.
Article
Pediatrics
Noga Givon-Lavi, Dana Danino, Bart Adriaan van der Beek, Amir Sharf, David Greenberg, Shalom Ben-Shimol
Summary: The COVID-19 pandemic resulted in a significant reduction in pediatric outpatient clinic visits and prescriptions, especially for respiratory conditions.
Article
Psychiatry
Dana Tzur Bitan, Khalaf Kridin, Noga Givon-Lavi, Israel Krieger, Ehud Kaliner, Arnon Dov Cohen, Orly Weinstein
Summary: This study found lower rates of COVID-19 vaccination among individuals with schizophrenia, especially during the booster vaccine phase. These gaps persisted even after adjusting for demographic and clinical variables. Countries worldwide should adopt strategies to reduce vaccination gaps and improve healthcare for this high-risk population.
Editorial Material
Psychiatry
Dana Tzur Bitan, Noga Givon-Lavi, Khalaf Kridin, Ehud Kaliner, Israel Krieger, Arnon Dov Cohen, Orly Weinstein